Risk for valvular heart disease after treatment for hodgkin lymphoma

Journal of the National Cancer Institute

Volumn 107, Issue 4, 2015, Pages

  Cutter, David J ^a   Schaapveld, Michael ^b   Darby, Sarah C ^a   Hauptmann, Michael ^b   Van Nimwegen, Frederika A ^b   Krol, Augustinus D G ^c   Janus, Cecile P M ^d   Van Leeuwen, Flora E ^b   Aleman, Berthe M P ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; AORTA VALVE; ARTICLE; CANCER SURVIVOR; CANCER THERAPY; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION RESPONSE; RISK ASSESSMENT; RISK FACTOR; SPLENECTOMY; STATISTICAL ANALYSIS; VALVULAR HEART DISEASE; ADVERSE EFFECTS; AGED; COMPARATIVE STUDY; HEART VALVE DISEASES; MIDDLE AGED; ODDS RATIO; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDY; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AORTIC VALVE; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEART VALVE DISEASES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; ODDS RATIO; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPLENECTOMY; TIME FACTORS; YOUNG ADULT;

EID: 84927557203     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv008     Document Type: Article

References (32)

1. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term causespecific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21(18):3431-3439.
2. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878-1886.
3. De Bruin ML, Dorresteijn LD, van't Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101(13):928-937.
4. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):2101-2108.
5. Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117(2):412-418.
6. Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49(8):1486-1493.
7. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206-214.
8. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831-2837.
9. Specht L, Yahalom J, Illidge T, et al. Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854-862.
10. Maraldo MV, Brodin NP, Vogelius IR, et al. Risk of Developing Cardiovascular Disease after Involved Node Radiotherapy versus Mantle Field for Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys. 2012;83(4):1232-1237.
11. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-998.
12. Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55(6):1145-1152.
13. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004;22(15):3139-3148.
14. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743-749.
15. Cella L, Liuzzi R, Conson M, et al. Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin's lymphoma. Radiother Oncol. 2011;101(2):316-321.
16. Machann W, Beer M, Breunig M, et al. Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2010;79(4):1117-1123.
17. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol. 1994;12(2):312-325.
18. van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18(3):487-497.
19. Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). USA: National Cancer Institute;2009.
20. Feng M, Moran JM, Koelling T, et al. Development and Validation of a Heart Atlas To Study Cardiac Exposure to Radiation Following Treatment for Breast Cancer. Int J Radiat Oncol Biol Phys. 2011;79(1):10-18.
21. Joiner MC, Van der Kogel AJ. Basic Clinical Radiobiology. 4th ed: Hodder Arnold;2009.
22. Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76(3):656-665.
23. Choudhury JB. Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med. 2002;21(8):1129-1144.
24. Plummer M. Improved estimates of floating absolute risk. Stat Med. 2004;23(1):93-104.
25. Stata Statistical Software: Version 11. In. College Station, TX: StataCorp;2009.
26. Epicure: Version 1.8. In. Seattle, WA: Hirosoft International Corporation.
27. Cella L, Liuzzi R, Conson M, et al. Multivariate normal tissue complication probability modeling of heart valve dysfunction in hodgkin lymphoma survivors. Int J Radiat Oncol Biol Phys. 2013;87(2):304-310.
28. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.
29. McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol. 2011;100(2):167-175.
30. Veinot JP. Pathology of inflammatory native valvular heart disease. Cardiovasc Pathol. 2006;15(5):243-251.
31. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-2879.
32. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997;29(3):630-634.